UK markets open in 4 hours 5 minutes
  • NIKKEI 225

    27,687.28
    +105.62 (+0.38%)
     
  • HANG SENG

    26,037.49
    +563.61 (+2.21%)
     
  • CRUDE OIL

    72.68
    +0.29 (+0.40%)
     
  • GOLD FUTURES

    1,815.10
    +15.40 (+0.86%)
     
  • DOW

    34,930.93
    -127.59 (-0.36%)
     
  • BTC-GBP

    28,590.32
    -179.52 (-0.62%)
     
  • CMC Crypto 200

    932.33
    +2.40 (+0.26%)
     
  • ^IXIC

    14,762.58
    +102.01 (+0.70%)
     
  • ^FTAS

    4,024.08
    +13.79 (+0.34%)
     

Cannovum AG enters supply agreement for medical cannabis with Aurora Europe

·2-min read

DGAP-News: Cannovum AG / Key word(s): Product Launch
24.06.2021 / 09:06
The issuer is solely responsible for the content of this announcement.

Cannovum AG (stock exchanges Düsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) has entered into a long term supply agreement with Aurora through its licensed subsidiary, Cannovum Health eG. Starting today, Cannovum will distribute the full range of medical cannabis products offered by Aurora to pharmacies throughout Germany.

The canadian company Aurora is one of the largest authorised manufacturers of medical cannabis in the European Union. After the German legalization of medical cannabis in 2017 Aurora joined the German market with their acquisition of the German company Pedanios, thus making Aurora / Pedanios products one of the first cannabis medicines available in Germany. This allowed doctors and pharmacists to gain experience in treating their patients with these products.
Expanding the medical cannabis portfolio with the full range of Aurora products is therefore an important step for Cannovum towards ensuring best possible patient care.

"We want to support doctors and pharmacists in finding the appropriate treatment for their patients. In order for us to achieve that, we need to provide a full portfolio of medical cannabis which gives them the opportunity to fully customize the therapy. By partnering with Aurora we are confident that we continue to provide high quality medication to ensure every patient receives the best therapy", says Pia Marten, CEO of Cannovum AG.

Cannovum's own team of pharmaceutical representatives has received intensive training in the new products, in order to confidently advise pharmacists and doctors.


Contact:

Linda Rasch, IR & PR, Cannovum AG
Phone +49 30 3982 163 62, linda.rasch@cannovum.com

Cannovum AG is the first German listed medical cannabis company. Through its subsidiary Cannovum Health eG, Cannovum is a fully licensed pharmaceutical wholesaler, importer and manufacturer of high-quality medical cannabis products based in Berlin. The company focuses on the import of high-quality cannabinoid products, medical-scientific education and all-encompassing distribution for simplified and facilitated access to cannabis-based therapies.

For more information, visit www.cannovum.com


24.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Cannovum AG

Rheinsberger Str. 76/77

10115 Berlin

Germany

Phone:

+49 (0)30 3982 16360

E-mail:

ir@cannovum.com

Internet:

www.cannovum.com

ISIN:

DE000A2LQU21

WKN:

A2LQU2

Listed:

Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich

EQS News ID:

1211413


 

End of News

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting